GVHD treatment with extracorporeal photopheresis in Brazil: a national survey

Fatobene, Giancarlo; Cordeiro, Ana; Mariano, Lívia Caroline Barbosa; Silva, Márcia; Bouzas, Luis Fernando; Hamerschlak, Nelson; Macedo, Maria Cristina Martins de Almeida; Petta, Alessandra; Funke, VAM; Novis, Yana; Flowers, Mary E.D.

doi:10.1016/j.htct.2021.11.018

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,7 It is a prevalent complication following HSCT that hurts both overall survival and quality of life. 12 It affects 40-60% of patients who undergo HSCT, contributing to 15-20% of deaths occurring after such transplantation. 2,6,9,13 The positive effects of GVT and GVHD are both perplexing.…”

Section: Introductionmentioning

confidence: 99%

The Role of Extracorporeal Photopheresis in the Management of Graft Versus Host Disease: Narrative Review

Berhan,

Damtie,

Almaw

et al. 2024

ITT

View full text Add to dashboard Cite

Hematopoietic stem cell donation is a method used to treat both blood-related and non-blood-related malignancies. Graft-versus-host disease is a potentially life-threatening complication that can occur following a stem cell transplant from a donor. This happens after the transplanted grafts attack the recipient’s body as foreign cells, causing significant morbidity and mortality. Clinically, this condition can be classified as acute or chronic based on onset and pathophysiology. This review aims to provide an overview of recent studies on extracorporeal photopheresis as a treatment strategy option for graft-versus-host-diseased patients. It will explain how it treats graft-versus-host disease, summarize its promising effects, and provide future recommendations for its use in treating this illness. Extracorporeal photopheresis is used to treat graft-versus-host disease by collecting and separating white blood cells from the patient. This blood is fractionated into different parts, and white blood cells undergo treatment with 8-methoxy psoralen, a photoactivable drug, before exposure to ultraviolet light A. Lastly, the cells that have been treated are reinfused into the recipient’s body. It prompts the programmed cell death of lymphocytes and the engulfment of cellular debris by host antigen-presenting, leading to a subsequent rise in T regulatory cells. However, more experimental and randomized controlled studies are required to identify the best patient selection requirements, environments, and treatment regimens for graft-versus-host disease.

show abstract